Literature DB >> 20579137

Medical treatment of benign prostatic hyperplasia: physician and patient preferences and satisfaction.

M Emberton1.   

Abstract

Practice guidelines acknowledge the importance of patient preferences in determining the appropriate treatment of benign prostatic hyperplasia (BPH). Recent literature suggests that patient and physician perspectives and satisfaction with BPH treatment management may differ; this may have an impact on clinical outcomes and patient compliance. This review evaluates patients' and physicians' preferred treatment options for managing BPH and patient satisfaction with therapy. A Medline-based systematic review using the terms 'Benign prostatic hyperplasia' + 'Patient preference/perception/satisfaction' or 'Physician/urologist preference/perception' was performed. Patients prefer therapies affecting long-term disease progression over those that provide short-term symptom improvement, which contrasts with the beliefs of their physicians. The prescribing behaviour of urologists and primary care physicians can be very varied. Studies of patient satisfaction with specific treatments generally show a high level of overall satisfaction, but cross-study comparisons are limited because of heterogeneity in study design. The evidence to date suggests that patients' views and beliefs and those of their physician may not always be in agreement. Improved physician-patient communication will help determine the best treatment option for patients with BPH and may ensure greater compliance and treatment success.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20579137     DOI: 10.1111/j.1742-1241.2010.02463.x

Source DB:  PubMed          Journal:  Int J Clin Pract        ISSN: 1368-5031            Impact factor:   2.503


  17 in total

1.  Patient's and physician's behavior on the management of benign prostatic hyperplasia among the patients at the risk of clinical progression. A multicenter noninterventional trial in Slovakia by "Prostate and Expectations of Treatment: Epidemiology Research" (PETER) study group.

Authors:  Peter Weibl; Peter Laurinc; Roman Tomaškin; Tobias Klatte; Shahrokh Shariat F; Miroslav Helbich; Danica Fačkovcova; Peter Bujdák
Journal:  Wien Klin Wochenschr       Date:  2015-03-28       Impact factor: 1.704

2.  Singapore Urological Association Clinical Guidelines for Male Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia.

Authors: 
Journal:  Singapore Med J       Date:  2017-08       Impact factor: 1.858

3.  Cross-cultural variation in preference for replantation or revision amputation: Societal and surgeon views.

Authors:  Brianna L Maroukis; Melissa J Shauver; Takanobu Nishizuka; Hitoshi Hirata; Kevin C Chung
Journal:  Injury       Date:  2016-03-02       Impact factor: 2.586

Review 4.  Methods to Summarize Discrete-Choice Experiments in a Systematic Review: A Scoping Review.

Authors:  Daksh Choudhary; Megan Thomas; Kevin Pacheco-Barrios; Yuan Zhang; Pablo Alonso-Coello; Holger Schünemann; Glen Hazlewood
Journal:  Patient       Date:  2022-07-13       Impact factor: 3.481

5.  Adherence to 5-alpha reductase inhibitor therapy for benign prostatic hyperplasia: clinical and economic outcomes.

Authors:  Stephen Gruschkus; Sara Poston; Michael Eaddy; Sham Chaudhari
Journal:  P T       Date:  2012-08

6.  Urinary and sexual function after treatment with temporary implantable nitinol device (iTind) in men with LUTS: 6-month interim results of the MT-06-study.

Authors:  Cosimo De Nunzio; Francesco Cantiello; Cristian Fiori; Fabio Crocerossa; Piero Tognoni; Daniele Amparore; Valeria Baldassarri; Javier Reinoso Elbers; Fernando Gomez Sancha; Francesco Porpiglia
Journal:  World J Urol       Date:  2020-08-26       Impact factor: 4.226

7.  Complaint handling in healthcare: expectation gaps between physicians and the public; results of a survey study.

Authors:  R D Friele; P M Reitsma; J D de Jong
Journal:  BMC Res Notes       Date:  2015-10-01

8.  Effect of combination treatment on patient-related outcome measures in benign prostatic hyperplasia: clinical utility of dutasteride and tamsulosin.

Authors:  Bob Djavan; Seyed Saeid Dianat; Amir Kazzazi
Journal:  Patient Relat Outcome Meas       Date:  2011-03-31

9.  Patients' and urologists' preferences for prostate cancer treatment: a discrete choice experiment.

Authors:  E W de Bekker-Grob; M C J Bliemer; B Donkers; M-L Essink-Bot; I J Korfage; M J Roobol; C H Bangma; E W Steyerberg
Journal:  Br J Cancer       Date:  2013-07-16       Impact factor: 7.640

10.  Drug-related problems in patients with benign prostatic hyperplasia: a cross sectional retrospective study.

Authors:  Hasniza Zaman Huri; Chong Hui Xin; Che Zuraini Sulaiman
Journal:  PLoS One       Date:  2014-01-27       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.